The first RIPTAC has just hit the clinic. Learn about this new technology that is being developed by Halda Therapeutics.

"Our study shows that FBXW7-R465C mutant can be targeted by bifunctional small molecules to break down harmful proteins." Zhang is a member of the Chemistry of Life Processes Institute (CLP).

VantAI today unveiled Neo-1, the world’s most advanced atomistic foundation model and the first to unify de novo molecular ...

The company is developing bifunctional cytokine molecules, IL-18-FHAB-IL12 and IL-18-FHAB. These molecules have an IL-18 domain that does not bind IL-18BP but maintains full IL-18 and IL-12 ...

The buy-in is another endorsement of Arvinas' PROTAC drugs, bifunctional molecules that use one arm to bind to a target protein, and the other to an enzyme involved in the main ubiquitin ...

SON-1411 is designed as a bifunctional fusion protein that combines IL-18BPR with IL-12, aiming to activate immune responses against tumors. Sonnet is positioning itself to advance its clinical ...